Vaxcyte Inc. (PCVX)
78.15
-3.02 (-3.72%)
At close: Jan 14, 2025, 3:59 PM
78.10
-0.06%
After-hours Jan 14, 2025, 05:01 PM EST
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 75.00M | 9.20M | 1.80M | 1.41M | 1.23M | 1.04M | n/a |
| Gross Profit | -75.00M | -9.20M | -1.80M | -1.41M | -1.23M | -1.04M | n/a |
| Operating Income | -468.04M | -232.26M | -103.67M | -89.58M | -54.15M | -35.53M | -17.83M |
| Interest Income | 62.91M | 8.36M | 344.00K | 244.00K | 632.00K | 903.00K | 164.00K |
| Pretax Income | -402.27M | -223.49M | -100.08M | -89.22M | -50.27M | -29.48M | -17.24M |
| Net Income | -402.27M | -239.64M | -100.08M | -87.82M | -53.50M | -29.48M | -17.24M |
| Selling & General & Admin | 60.70M | 39.81M | 25.26M | 16.02M | 8.55M | 5.39M | 5.05M |
| Research & Development | 332.34M | 169.45M | 78.41M | 73.56M | 45.61M | 30.14M | 12.79M |
| Other Expenses | n/a | -1.93M | -1.58M | -2.48M | -237.00K | 5.18M | n/a |
| Operating Expenses | 468.04M | 207.33M | 102.08M | 87.10M | 53.92M | 35.53M | 17.40M |
| Interest Expense | n/a | 2.00K | 7.00K | 7.00K | 40.00K | 75.00K | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 468.04M | 207.33M | 102.08M | 87.10M | 53.92M | 35.53M | 17.40M |
| Income Tax | n/a | 16.16M | 7.00K | -1.40M | 3.23M | 6.12M | n/a |
| Shares Outstanding (Basic) | 97.16M | 64.88M | 51.92M | 51.07M | 48.86M | 25.60M | 3.56M |
| Shares Outstanding (Diluted) | 97.16M | 64.88M | 51.92M | 51.07M | 48.86M | 25.60M | 3.57M |
| EPS (Basic) | -4.14 | -3.69 | -1.93 | -1.72 | -1.09 | -1.15 | -4.84 |
| EPS (Diluted) | -4.14 | -3.69 | -1.93 | -1.72 | -1.09 | -1.15 | -4.83 |
| EBITDA | -464.88M | -214.29M | -98.28M | -87.81M | -49.00M | -28.37M | -17.21M |
| Depreciation & Amortization | 3.16M | 9.20M | 1.80M | 1.41M | 1.23M | 1.04M | 625.00K |